Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 65 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: tenofovir alafenamide fumarate (TAF) Clear all
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

NCT02600819
View directory record Official record
Conditions
HIV-1 Infection
Interventions
E/C/F/TAF, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Los Angeles, California • Sacramento, California • Ft. Pierce, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

NCT01815736
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
91
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 10, 2026, 1:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK and PD Study of Oral F/TAF for HIV Prevention

NCT02904369
View directory record Official record
Conditions
HIV
Interventions
Emtricitabine, Tenofovir alafenamide, Tenofovir disoproxil
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

NCT02121795
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/TDF, F/TAF, Allowed third antiretroviral agent, FTC/TDF Placebo, F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 10, 2026, 1:42 PM EDT
Completed Phase 2 Interventional Results available

Early ART to Limit Infection and Establishment of Reservoir

NCT02859558
View directory record Official record
Conditions
HIV-1 Infection
Interventions
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • San Diego, California • Torrance, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults

NCT02071082
View directory record Official record
Conditions
HIV, HBV
Interventions
E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
21
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 10, 2026, 1:42 PM EDT
Completed No phase listed Observational

Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen

NCT03646370
View directory record Official record
Conditions
HIV-1-infection, Metabolic Syndrome, Cardiovascular Diseases, Weight Gain, Renal Function Abnormal, Hyperglycemia
Interventions
Tenofovir Alafenamide
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 10, 2026, 1:42 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection

NCT05763576
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
RO7565020, Placebo, Nucleos(t)ide analogue (NUC) treatment
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 10, 2026, 1:42 PM EDT
Withdrawn Phase 2 Interventional

Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis

NCT04880577
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Fatigue
Interventions
TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY], Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

NCT02603107
View directory record Official record
Conditions
HIV-1 Infection
Interventions
RTV, ATV, DRV, COBI, ATV/co, DRV/co, FTC/TDF, ABC/3TC, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
63
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 10, 2026, 1:42 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers Results available

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection

NCT04925752
View directory record Official record
Conditions
Pre-Exposure Prophylaxis of HIV Infection
Interventions
Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
3,292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
60
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

NCT02345252
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/RPV/TAF, FTC/RPV/TDF Placebo, FTC/RPV/TDF, FTC/RPV/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
632 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 10, 2026, 1:42 PM EDT
Terminated Phase 2 Interventional Results available

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

NCT04454567
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H0731, Placebo, NrtI
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Los Angeles, California • Pasadena, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 10, 2026, 1:42 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans

NCT06766331
View directory record Official record
Conditions
Opioid Use Disorder, HIV, Hepatitis C Virus, Gonorrhea, Chlamydia, Syphilis, Sexually Transmitted Infection, Integrated Care, Medications for Opioid Use Disorder
Interventions
Integrated care
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2028 – 2029
U.S. locations
1
States / cities
Northport, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 10, 2026, 1:42 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study

NCT05652478
View directory record Official record
Conditions
Healthy Volunteer, Weight Gain, Metabolic Effects, Integrase Strand Transfer Inhibitors
Interventions
Dolutegravir (DTG) AND Tenofovir alafenamide (TAF), Tenofovir Disoproxil Fumarate, Dolutegravir, Tenofovir alafenamide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

NCT02652624
View directory record Official record
Conditions
HIV-1 Infection
Interventions
E/C/F/TAF, E/C/F/TDF, ATV, RTV, FTC/TDF, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
29
States / cities
Stamford, Connecticut • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

NCT02707601
View directory record Official record
Conditions
HIV-1 Infection, HCV Infection
Interventions
E/C/F/TAF, F/R/TAF, LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen

NCT01940471
View directory record Official record
Conditions
HBeAg-positive Chronic Hepatitis B
Interventions
TAF, TDF, TAF Placebo, TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 10, 2026, 1:42 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

NCT02016924
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

NCT02269917
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1
Interventions
D/C/F/TAF, Boosted Protease Inhibitor (bPI), FTC/TDF
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
38
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 10, 2026, 1:42 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

NCT06630299
View directory record Official record
Conditions
HIV-1-Infection
Interventions
ISL/LEN, Antiretroviral Combinations
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 10, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

NCT02616029
View directory record Official record
Conditions
HIV-1 Infection
Interventions
E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Ft. Pierce, Florida • Orlando, Florida • West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 10, 2026, 1:42 PM EDT
Recruiting No phase listed Observational

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

NCT07473778
View directory record Official record
Conditions
HIV Infections
Interventions
Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Timeline
2026 – 2029
U.S. locations
39
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 10, 2026, 1:42 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection

NCT03576066
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H0731, SOC NUC, Placebo Oral Tablet
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
17
States / cities
Beverly Hills, California • Coronado, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 10, 2026, 1:42 PM EDT